What Oscotec does

Oscotec Inc. is a Seongnam, South Korea-based clinical-stage drug discovery company that discovers and develops small-molecule and antibody therapeutics in immunology and oncology. Founded in 1998 and KOSDAQ-listed (kosdaq:039200) since 2007, the company operates its central R&D center from Korea Bio-Park with a Boston-based R&D subsidiary (Genosco Inc., separated in 2016) and maintains a lean organization of 11–50 employees. Its pipeline comprises six named drug candidates built around novel mechanisms of action: Lazertinib (third-generation EGFR inhibitor), Cevidoplenib (SYK inhibitor), Denfivontinib (FLT3/AXL dual inhibitor), Adel-Y01 (anti-acetylated-tau monoclonal antibody), OCT-598 (EP2/4 dual antagonist), and OCT-648 (NUAK1 inhibitor). The discovery engine relies on hypothesis-driven medicinal chemistry and rigorous target-disease validation, with scientific leadership drawn from Yale, Caltech, the University of Pennsylvania, Novartis Pharma, and Dong-A ST.

The company's business model is asset-centric out-licensing rather than direct commercialization. Oscotec advances candidates to clinical proof-of-concept or key regulatory milestones, then transfers global development and commercialization rights to pharmaceutical partners in exchange for upfront payments, development and regulatory milestones, and tiered royalties. Disclosed deal economics include the 2018 Yuhan-to-Janssen transfer for Lazertinib ($1.255 billion total), the December 2025 Sanofi license for Adel-Y01 ($80 million upfront plus up to $1.04 billion total deal value), and the June 2026 Agios license for Cevidoplenib ($25 million upfront plus up to $140 million in milestones). Recurring royalty revenue flows from Lazertinib, where Oscotec retains 10–15% of net sales through a 6:2:2 distribution arrangement with Yuhan and Genosco; Q1 2025 royalty receipts were KRW 1.289 billion.

The customer base consists entirely of global pharmaceutical partners: Sanofi, Janssen/Johnson & Johnson, Yuhan Corporation, Agios Pharmaceuticals, Yatiri Bio, and ADEL Inc. The company supplements in-house discovery with co-development agreements, including Kanaph Therapeutics (EP2/4 program), Beactica (LSD1), Biorevert (BRVT121/221), and ADEL (Adel-Y01), and pursues new partnerships through industry events such as BIO USA. The lean headcount and absence of commercial infrastructure are consistent with a discovery-engine operating model that monetizes innovation through licensing rather than through integrated pharmaceutical sales.

Name

Oscotec

Legal name

Oscotec Inc.

Website

https://oscotec.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Oscotec is a Seongnam, South Korea-based clinical-stage biotech that discovers small-molecule and antibody therapeutics in oncology and immunology, advancing six candidates through out-licensing partnerships with global pharmaceutical companies for milestone and royalty revenue.

Ownership category

akta.pro rank

Product category

Clinical-stage drug discovery and development

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Drug discovery services
• Small molecule therapeutics
• Clinical stage biotech
• Targeted oncology therapies
• Immunology drug development

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Licensing Royalties: Oscotec receives royalty revenues based on sales performance of licensed drugs. For Lazertinib, royalties are distributed among Yuhan, Oscotec, and Genosco in a 6:2:2 ratio, with Oscotec receiving 10-15% of net sales globally.
2. Milestone Payments: Upfront and development/regulatory milestone payments from licensing agreements. Cevidoplenib deal with Agios: $25M upfront plus up to $140M in milestones. Adel-Y01 deal with Sanofi: $80M upfront with potential total value up to $1.04B.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Oscotec is a clinical-stage drug discovery company that discovers and develops small-molecule targeted therapeutics and biologics with novel mechanisms of action in oncology and immunology. The company monetizes its pipeline through out-licensing deals with global pharmaceutical partners, receiving upfront payments, development and regulatory milestones, and tiered royalties on net sales.

Product overview

Oscotec is a clinical-stage South Korean drug discovery and development company focused on targeted therapeutics in immunology and oncology. The company's pipeline consists of six named drug candidates: Lazertinib (EGFR inhibitor, partnered with Janssen), Cevidoplenib (SYK inhibitor, licensed to Agios), Denfivontinib (FLT3/AXL inhibitor), Adel-Y01 (anti-Tau antibody, licensed to Sanofi), OCT-598 (EP2/4 antagonist), and OCT-648 (NUAK1 inhibitor). Oscotec operates a discovery engine model, identifying small molecules with novel mechanisms of action and validating drug-target-disease hypotheses through rigorous science to clinical proof-of-concept.

Differentiator

Problem solved

Functional benefit

Brands

• SKI-O-703: SYK inhibitor program by Oscotec
• Denfivontinib
• SKI-G-801
• SKI-G-749

Products and services

• Lazertinib (YH25448) Third-generation EGFR inhibitor for EGFR-mutant non-small cell lung cancer (NSCLC). Licensed to Yuhan Corporation and sublicensed to Janssen Biotech for USD 1.255 billion in 2018. Demonstrated extended overall survival by more than 12 months compared to Tagrisso in Phase 3 MARIPOSA trial when combined with Rybrevant.
• Cevidoplenib (SKI-O-703) Selective SYK inhibitor for rheumatoid arthritis (RA) and immune thrombocytopenia (ITP). Demonstrated excellent safety profile in Phase 2 trials with rapid onset of clinical response within two weeks. In high-dose treatment group, 73% of patients achieved greater than or equal to 2-fold increase in platelet counts versus 25% on placebo, and 41% of patients reached platelet counts greater than or equal to 50,000/microL.
• Denfivontinib (SKI-G-801) FLT3/AXL dual inhibitor for acute myeloid leukemia (AML) and solid tumors. Addresses FLT3 mutations found in approximately 30-35% of AML patients and AXL overexpression associated with therapy resistance in solid tumors. Demonstrated anti-leukemic activity in patient-derived samples and immune-dependent anti-tumor effects.
• Adel-Y01 Anti-Tau monoclonal antibody targeting acetylated K280 (acK280) epitope for Alzheimer's disease. Selectively targets disease-specific pathological tau rather than normal tau. Co-developed with ADEL Inc. Holds first-in-class potential among anti-Tau antibodies.
• OCT-598 EP2/4 dual antagonist for solid tumors. Targets prostaglandin E2 signaling to prevent tumor recurrence by inhibiting cancer cell regeneration and therapy resistance.
• OCT-648 NUAK1 inhibitor targeting renal fibrosis and chronic kidney disease (CKD). Novel mechanism modulating YAP/TAZ signaling pathway with demonstrated anti-fibrotic efficacy in preclinical models.

Quantifiable outcome

• Lazertinib combination therapy extended overall survival by more than 12 months compared to Tagrisso in Phase 3 MARIPOSA trial
• +3 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered major, moderate, minor and internal.

• Agios PharmaceuticalsmajorTechnology or Integration · 1 June 2026Agios licensed exclusive global rights to Oscotec's cevidoplenib (next-generation SYK inhibitor) for immune thrombocytopenia. Oscotec received $25 million upfront with potential additional payments of up to $140 million in development and regulatory milestones plus tiered royalties on future net sales. Agios plans Phase 3 trials for ITP in H1 2028, targeting peak U.S. sales potential of up to $1 billion.
• Yatiri BiomoderateStrategic or Co-development Partner · 24 March 2026Yatiri Bio entered exclusive option to in-license denfivontinib (FLT3/AXL dual inhibitor) for acute myeloid leukemia (AML). This provides Yatiri access to Oscotec's oncology asset.
• SanofimajorTechnology or Integration · 15 December 2025Sanofi licensed global rights to ADEL-Y01 (anti-Tau antibody for Alzheimer's disease) co-developed with Oscotec since 2020. Deal valued at up to $1.04 billion including $80M upfront and additional milestone payments plus royalties. The antibody targets acetylated K280 (acK280) epitope and holds first-in-class potential.
• Biorevert Inc.minorStrategic or Co-development Partner · 1 January 2023Co-development agreement for BRVT121 and BRVT221. Biorevert partnership expands Oscotec's pipeline in additional therapeutic areas.
• Kanaph TherapeuticsmoderateStrategic or Co-development Partner · 1 March 2022Co-development agreement for EP2/4 program (OCT-598). Kanaph brings genome-driven drug target discovery capabilities; partnership worth approximately KRW 774.8 billion in cumulative deal value.
• Beactica Therapeutics ABminorStrategic or Co-development Partner · 1 March 2021Joint R&D agreement for LSD1 program. Beactica contributes specialized drug discovery capabilities.
• ADEL Inc.majorStrategic or Co-development Partner · 1 October 2020Co-development agreement for ADEL-Y01 (anti-Tau antibody for Alzheimer's disease). Oscotec contributed discovery expertise; ADEL advanced the program through Phase 1 before out-licensing to Sanofi in December 2025.
• Ectodor Therapeutics Inc.internalOthers · 1 October 2020Oscotec established Ectodor Therapeutics Inc. as a subsidiary in October 2020 to support broader corporate strategy.
• Janssen Pharma (Johnson & Johnson)majorTechnology or Integration · 1 November 2018Janssen licensed Lazertinib from Yuhan (which licensed from Oscotec subsidiary Genosco). Deal valued at $1.255 billion. Lazertinib is a 3rd generation EGFR inhibitor. FDA approved combination with Rybrevant in August 2024.
• Yuhan CorporationmajorTechnology or Integration · 1 July 2015Oscotec licensed EGFR-targeted anti-cancer drug candidate (Lazertinib) to Yuhan in 2015. Yuhan further licensed to Janssen in 2018 for $1.255 billion. Yuhan distributes royalties to Oscotec (10-15% of net sales, distributed 6:2:2 with Genosco).

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oscotec